SORBENT COMPRISING ON ITS SURFACE A CATIONIC OR PROTONIZABLE ALIPHATIC RESIDUE FOR THE PURIFICATION OF ORGANIC MOLECULES

The present invention relates to a sorbent comprising a solid support material, the surface of which comprises a residue of a general formula (I), wherein the residue is attached via a covalent single bond to a functional group on the surface of either the bulk solid support material itself or of a polymer film on the surface of the solid support material. Furthermore, the present invention relates to the use of the sorbent according to the invention for the purification of organic molecules, in particular pharmaceutically active compounds, preferably in chromatographic application. 115-. (canceled)17. The sorbent of claim 16 , wherein Pis a group composing at least one nitrogen atom in the form of an amine.18. The sorbent of claim 17 , wherein the amine is a primary claim 17 , secondary claim 17 , tertiary or quaternary amine.22. The sorbent of claim 16 , wherein h is 1.24. The sorbent of claim 16 , wherein the sorbent comprises two or more different residues of formula (I).25. The sorbent of claim 16 , wherein the surface of the solid support material is covered with a polymer film comprising individual chains which are covalently crosslinked with each other claim 16 , and wherein the individual chains are not covalently bound to the surface of the solid support material.26. The sorbent of claim 25 , wherein the polymer is a polyamine claim 25 , a polyvinylamine claim 25 , a copolymer comprising polyamine or a polymer blend comprising polyamine.27. A method for the purification of organic molecules claim 16 , comprising contacting organic molecules with the sorbent of .28. The method of claim 27 , wherein the organic molecules comprise one or more anionic or deprotonizable groups and/or a plurality of hydroxyl or chloro groups.29. The method of claim 27 , wherein the organic molecules exhibit a molecular weight in a range of from 100 to 200000 g/mol.30. The method of claim 27 , wherein the organic molecules are selected from the group consisting of paclitaxel ...

Storage-stable dye solutions

The present invention relates to storage-stable dye salts, solutions and compositions thereof a process for their preparation and their use for dyeing and/or printing substrates.

COMPOUNDS FOR USE IN THE TREATMENT OF IMMUNE RELATED INFLAMMATORY DISEASE

Compounds particularly for use in an autoimmune inflammatory disease and especially the treatment of inflammatory bowel disease have the formula: wherein R is selected from one or more of the same or different of hydrogen, hydroxyl, optionally substituted alkyl, optionally substituted aryl, alkoxy, aryloxy, thiol, and optionally substituted amino, and wherein Ris selected from one or more of the same or different of hydrogen, acetyl, optionally substituted alkyl, optionally substituted aryl, and an amino acid selected from leucine, valine, isoleucine, and glycine. 119-. (canceled)22. The compound as claimed in wherein alkyl contains from 1 to 10 carbon atoms in a straight or branched chain and may be saturated or unsaturated claim 20 , or cycloalkyl groups containing 3 to 8 carbon atoms which may be saturated or unsaturated.23. The compound as claimed in wherein alkyl is substituted with one or more of the same or different from alkyl claim 20 , alkoxy claim 20 , alkylamino claim 20 , amido claim 20 , amino claim 20 , aryl claim 20 , aralkyl claim 20 , aryloxy claim 20 , carboxy claim 20 , halo claim 20 , hydroxy claim 20 , nitrile claim 20 , nitro or oxo groups.24. The compound as claimed in wherein aryl is substituted with one or more of the same or different from alkyl claim 20 , alkoxy claim 20 , alkylamino claim 20 , amido claim 20 , amino claim 20 , anhydride claim 20 , aryl claim 20 , aralkyl claim 20 , aryloxy claim 20 , carboxy claim 20 , halo claim 20 , hydroxy claim 20 , nitrile claim 20 , nitro claim 20 , or oxo groups.25. The compound as claimed in wherein amino is substituted with one or more of the same of different from alkyl claim 20 , hydroxyalkyl claim 20 , aryl claim 20 , and substituted aryl.26. The compound as claimed in wherein amino is substituted with aryl substituted by one or more of OH claim 25 , NH claim 25 , and COOH.27. The compound as claimed in wherein R is OH.28. The compound as claimed in wherein Ris H.31. The pharmaceutical ...

Methods of reducing color in alkanolamine compositions and compositions produced thereby

A method of reducing color in an alkanolamine, the method comprising: contacting the alkanolamine with an amount of an aqueous solution effective to provide 5 to 1000 parts per million by weight of an alkali metal borohydride, based on parts by weight of the alkanolamine; and 0.5 to 10,000 parts per million by weight of an alkali metal hydroxide, based on parts by weight of the alkanolamine; preferably wherein the color-reduced alkanolamine is not distilled after the contacting.

NRF2 ACTIVATORS

The present invention relates to a compound which is (R)-3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydropyrido[2,3-f][1,4]oxazepin-4(5H)-yl)methyl)-4-methylphenyl)propanoic acid (I), or a pharmaceutically acceptable salt thereof, in particular, the meglumine salt thereof, a pharmaceutical composition containing the compound and its use as an NRF2 activator. 110-. (canceled)12. A pharmaceutical composition comprising the compound of and one or more pharmaceutically acceptable excipients.13. A method of treating respiratory and non-respiratory disorders claim 11 , including COPD claim 11 , asthma claim 11 , ALI claim 11 , ARDS claim 11 , fibrosis claim 11 , chronic asthma claim 11 , acute asthma claim 11 , lung disease secondary to environmental exposures claim 11 , acute lung infection claim 11 , chronic lung infection claim 11 , al antitrypsin disease claim 11 , cystic fibrosis claim 11 , autoimmune diseases claim 11 , diabetic nephropathy claim 11 , chronic kidney disease claim 11 , sepsis-induced acute kidney injury claim 11 , AKI claim 11 , kidney disease or malfunction seen during kidney transplantation claim 11 , Pulmonary Arterial Hypertension claim 11 , hypertension claim 11 , heart failure claim 11 , acute coronary syndrome claim 11 , myocardial infarction claim 11 , myocardial repair claim 11 , cardiac remodeling claim 11 , cardiac arrhythmias claim 11 , heart failure with preserved ejection fraction claim 11 , heart failure with reduced ejection fraction claim 11 , diabetic cardiomyopathy atherosclerosis claim 11 , PD claim 11 , AD claim 11 , FA claim 11 , ALS claim 11 , MS claim 11 , inflammatory bowel disease claim 11 , colon cancer claim 11 , neovascular (dry) AMD and neovascular (wet) AMD claim 11 , eye injury claim 11 , FECD claim 11 , uveitis or other inflammatory eye conditions claim 11 , NASH claim 11 , toxin-induced liver disease claim 11 , including acetaminophen-induced hepatic disease claim 11 , viral hepatitis ...

Novel organic crystalline salt of haloacetic acid

The present invention specifically relates to novel salt and crystalline form of haloacetic acid and its process of preparation. The invention more particularly relates to novel crystalline form dichloroacetate tromethamine salt and its process of preparation. The present invention more specifically relates to the dichloroacetate tromethamine salt, its process and its use for the treatment of various diseases and/or disorders.

AMINE SYNERGISTS

The present disclosure is drawn to an amine synergist including a tertiary benzylamine with a substituted benzene ring attached to a tertiary amine. The tertiary amine can be modified with multiple water soluble groups. 1. An amine synergist , comprising a tertiary benzylamine including a substituted benzene ring attached to a tertiary amine , wherein the tertiary amine is modified with multiple water soluble groups.2. The amine synergist of claim 1 , wherein one or more of the water soluble groups is C2 to C5 alkyl hydroxyl claim 1 , C2 to C5 alkyl sulfonate claim 1 , C2 to C5 alkyl sulfonic acid claim 1 , C2 to C5 alkyl carboxylate claim 1 , C2 to C5 alkyl carboxylic acid claim 1 , or polyethylene glycol with from 2 to 20 ether groups.3. The amine synergist of claim 1 , wherein the substituted benzene ring is provided by a diphenyl(2 claim 1 ,4 claim 1 ,6-trimethylbenzoyl)phosphine oxide.5. The amine synergist of claim 4 , wherein A is hydroxyl claim 4 , sulfonate claim 4 , sulfonic acid claim 4 , carboxylate claim 4 , carboxylic acid claim 4 , or polyethylene glycol with from 2 to 20 ether groups.7. The amine synergist of claim 6 , wherein A is hydroxyl claim 6 , sulfonate claim 6 , sulfonic acid claim 6 , carboxylate claim 6 , carboxylic acid claim 6 , or polyethylene glycol with from 2 to 20 ether groups.9. A photo curable ink claim 6 , comprising:a photo reactive binder;an amine synergist comprising a tertiary benzylamine including a substituted benzene ring attached to a tertiary amine, wherein the tertiary amine is modified with multiple water soluble groups;a Type II photo initiator;a colorant; anda liquid vehicle including co-solvent and water.10. The photo curable ink of claim 9 , wherein the photo curable ink has a pH from 7 to 12 and the amine synergist is stable in the photo curable ink.11. The photo curable ink of claim 9 , wherein the Type II photo initiator is a polymeric photo initiator and wherein the photo curable ink further comprises a co-photo ...

Immunomodulator compounds

including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2a, R2b, R2c, R3, R4, R5, R6a, R6b, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Lipids for delivery of active agents

Compounds are provided having the following structure: Formula (I) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R, R 1 , R 2 , G 1 , G 2 and n are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.

POLYETHER POLYOL PROVIDING GOOD BLOW-GEL BALANCE FOR POLYURETHANE PRODUCTS MADE THEREFROM

The present invention discloses a tertiary amine initiator and polymeric polyol compositions made therefrom useful for making polyurethane polymers, especially polyurethane foams. Said polyurethane polymer foams demonstrate a good balance of mechanical properties, physical properties and low emissions. The tertiary amine initiator is the reaction product of a dihydroxy tertiary amine and a polyhydroxy alcohol, such as the reaction product of N-methyl ethanolamine and glycerine. 2. The polyol initiator of wherein the mole ratio of dihydroxy tertiary amine compound to the polyhydroxy alcohol is 10:1 to 1:10.3. The polyol initiator of or wherein Ris methyl and Rand Rare both ethyl and the polyhydroxy alcohol is glycerine.5. A process to make a polyurethane polymer by reaction of a mixture comprising:(A) a polymeric polyol formulation comprising:{'claim-ref': {'@idref': 'CLM-00004', 'claim 4'}, '(i) the first polymeric polyol composition of ;'}(B) at least one organic isocyanate;(C) optionally a blowing agent;and(D) optionally additives or auxiliary agents known per se for the production of polyurethane polymers.7. The process of or wherein the reaction occurs in the presence of a blowing agent and the polyurethane polymer is produced in the form of a polyurethane flexible foam. The present invention pertains to a novel tertiary amine initiator and polymeric polyol compositions made therefrom useful for making polyurethane polymers, especially polyurethane foams; said polyurethane polymer foams demonstrating a good balance of mechanical properties, physical properties, and low volatile organic compounds emissions.Polyether polyols based on the polymerization of alkylene oxides, and/or polyester polyols, are the major components of a polyurethane system together with isocyanates. Polyols can also be filled polyols, such as SAN (styrene/acrylonitrile), PIPA (polyisocyanate polyaddition) or PHD (polyurea) polyols. These systems generally contain additional components such ...

SYNERGISTIC COMPOSITIONS

The present invention describes a synergistic composition comprising of one or more statins, or one or more dipeptidyl peptidase IV (DPP IV) inhibitor or one or more biguanide antihyperglycaemic agent and a PPAR agonist of formula (Ia) 2. The synergistic composition as claimed in claim 1 , wherein the one or more DPP IV inhibitors are selected from Sitagliptin claim 1 , Vildagliptin claim 1 , Saxagliptin claim 1 , Alogliptin and Linagliptin.3. The synergistic composition as claimed in claim 1 , wherein the one or more statins are selected from Lovastatin claim 1 , Pravastatin claim 1 , Fluvastatin claim 1 , Simvastatin claim 1 , Atorvastatin claim 1 , Rosuvastatin and Pitavastatin.4. The synergistic composition as claimed in claim 1 , wherein the one or more biguanide antihyperglycaemic agents are selected from Metformin claim 1 , Buformin or Phenformin.5. The synergistic composition as claimed in claim 1 , wherein the one or more thiazolidinediones are selected from Pioglitazone and Rosiglitazone.6. The synergistic composition as claimed in claim 1 , wherein the one or more sulphonylureas are selected from glibenclamide claim 1 , glipizide claim 1 , gliclazide claim 1 , glimepiride claim 1 , tolazamide claim 1 , tolbutamide claim 1 , acetohexamide claim 1 , carbutamide claim 1 , chlorpropamide claim 1 , glibomuride claim 1 , gliquidone claim 1 , glisentide claim 1 , glisolamide claim 1 , glisoxepide claim 1 , glyclopyamide claim 1 , glycylamide and glipentide.7. The synergistic composition as claimed in claim 1 , wherein the one or more SGLT-2 inhibitors are selected from Dapagliflozin claim 1 , Canagliflozin claim 1 , Empagliflozin claim 1 , Ertugliflozin and Ipragliflozin.8. The synergistic composition as claimed in claim 1 , wherein the one or more GLP-1 agonists are selected from Exenatide claim 1 , Liraglutide and Dulaglutide.9. (canceled)10. A method for the treatment of dyslipidemia claim 1 , hypertriglyceridemia or diabetes mellitus which comprises ...

NOVEL SYNTHETIC ANALOGS OF SPHINGOLIPIDS

The present invention provides new ceramide analogs indicated as the compounds of formula (II). These novel analogs exhibit a significant anti cancerous effect and are therefore provided as a pharmaceutical composition for treating cell proliferative diseases, neurodegenerative disorders, metabolism-associated conditions, infectious diseases, and immune-related disorders. The invention further provides combined compositions and kits combining the novel ceramide analogs of formula (II) with an additional therapeutic agent. 2. A compound of formula (II) according to claim 1 , wherein Rrepresents a Clinear or branched alkyl.3. A compound of formula (II) according to claim 1 , wherein W represents CHOH.5. A pharmaceutical composition comprising a compound of formula (II) according to claim 1 , or any pharmaceutically acceptable salt or isomer thereof claim 1 , and optionally further comprising at least one pharmaceutically acceptable carrier claim 1 , diluent claim 1 , excipient and/or additive.6. A pharmaceutical composition according to claim 5 , further comprising at least one additional therapeutic agent.7. A pharmaceutical composition according to claim 5 , for the treatment of a pathological disorder selected from the group consisting of proliferative disorders claim 5 , immune-related disorders claim 5 , neurodegenerative disorders claim 5 , infectious diseases and metabolism-associated conditions.8. A composition comprising a combination of at least one compound of formula (II) according to or a pharmaceutically acceptable salt or isomer thereof claim 1 , and at least one additional therapeutic agent claim 1 , optionally further comprising at least one pharmaceutically acceptable carrier claim 1 , diluent claim 1 , excipient and/or additive.9. A composition according to claim 8 , wherein said additional therapeutic agent is selected from topoisomerase inhibitors claim 8 , nucleic acids antimetabolites claim 8 , and antimitotic agents.10. A composition according ...

SYNTHESIS OF DEUTERATED MORPHOLINE DERIVATIVES

The present invention is directed to a process for preparing a 2,26,6-d-morpholine derivative represented by Structural Formula (I): 110.-. (canceled)12. The compound of claim 11 , wherein the deuterium enrichment at each position designated as deuterium is at least about 85%.13. The compound of claim 12 , wherein R claim 12 , R claim 12 , Rand R are each —H; Ris benzyl; and the deuterium enrichment at each position designated as deuterium is 95%.15. The compound of claim 14 , wherein each of R claim 14 , R claim 14 , Rand R is hydrogen claim 14 , or a salt thereof; and wherein the deuterium enrichment at each position designated as deuterium is at least about 95%.16. The compound of claim 14 , wherein Ris benzyl claim 14 , —SO-aryl claim 14 , or —SO-heteroaryl.17. The compound of claim 15 , wherein Ris benzyl.18. The compound of claim 14 , wherein Ris alkyl optionally substituted with one or more groups selected from halogen claim 14 , Calkyl claim 14 , —NO claim 14 , —CN claim 14 , —NH claim 14 , —NHR claim 14 , —N(R) claim 14 , —C(═O)NRR claim 14 , and —SONRR claim 14 , wherein each Calkyl substituent is optionally substituted with one or more groups selected from halogen claim 14 , Calkyl claim 14 , Calkoxy claim 14 , —OH claim 14 , Chaloalkyl and Chaloalkoxy.20. A pyrogen-free pharmaceutical composition comprising the compound of ; and a pharmaceutically acceptable carrier.21. A composition comprising the compound of ; and a pharmaceutically acceptable carrier for use in treating a bacterial infection or a fungal disorder in a subject in need thereof.22Enterococcus faecium, Staphylococcus aureus, Streptococcus agalactiae, Streptococcus pneumoniae, Streptococcus pyrogenes, Enterococcus faecalis, Staphylococcus epidermidis, Staphyloccocus haemolyticusPasteurella multocida.. The composition of claim 21 , wherein the bacterial infection is caused by a bacteria selected from claim 21 , and23Enterococcus faeciumStaphylococcus aureusStreptococcus ...

Salts of fenofibric acid and pharmaceutical formulations thereof

In one aspect, the present invention relates to a formulation in the form of molecular dispersion comprising i) fenofibric acid, a physiologically acceptable salt or derivative thereof and optionally other active substances, ii) a binder component comprising at least one enteric binder, and optionally iii) other physiologically acceptable excipients. In a second aspect, the present invention relates to novel salts of fenofibric acid that are photostable when compared to other salts of fenofibric acid.

Steroids as Agonists for FXR

The invention relates to compounds of formula (I): 2. The sodium salt of the compound of .3. The lithium salt of the compound of .4. The potassium salt of the compound of .5. The hemicalcium salt of the compound of .6. The hemimagnesium salt of the compound of .7. The hemizinc salt of the compound of .8. The choline salt of the compound of .9. The diethanolamine salt of the compound of .10. The N-methylglucamine salt of the compound of . This application is a continuation of U.S. patent application Ser. No. 14/632,139, filed Feb. 26, 2015, which is a continuation of Ser. No. 13/761,889, filed Feb. 7, 2013, now U.S. Pat. No. 8,969,330, which is a continuation of U.S. patent application Ser. No. 13/288,558, filed Nov. 3, 2011, now U.S. Pat. No. 8,377,916, which is a continuation of U.S. patent application Ser. No. 12/547,147, filed Aug. 25, 2009, now U.S. Pat. No. 8,058,267, which is a continuation of U.S. patent application Ser. No. 11/602,307, filed Nov. 21, 2006, now U.S. Pat. No. 7,786,102, which is a continuation of U.S. patent application Ser. No. 10/471,549, filed Sep. 11, 2003, now U.S. Pat. No. 7,138,390, which claims priority under 35 U.S.C. Section 371 to PCT Patent Application No. PCT/EP02/01832, filed Feb. 21, 2002, which claims priority to U.S. Patent Application No. 60/274,959, filed Mar. 12, 2001, the disclosures of each of which are incorporated by reference herein in their entirety.The present invention relates to Farnesoid X receptors (FXR). More particularly, the present invention relates to compounds useful as agonists for FXR, pharmaceutical formulations comprising such compounds, and therapeutic use of the same.Farnesoid X Receptor (FXR) is an orphan nuclear receptor initially identified from a rat liver cDNA library (B M. Forman, et al., 81:687-693 (1995)) that is most closely related to the insect ecdysone receptor. FXR is a member of the nuclear receptor family of ligand-activated transcription factors that includes receptors for the steroid, ...

Aminoalcohol compounds and their use as zero or low voc additives for paints and coatings

Provided are aminoalcohol compounds for use as additives in paints and coatings. The compounds are of the formula I: wherein p, m, n, R, R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are as defined herein.

Organic Amine Salt Compound Having Anions Serving as CO2 Donors and Application of Same as Foaming Agent

A foaming agent comprising organic amine salt compounds of the following general formula A [B](I) is disclosed, wherein A is a CO-donating anion with a valence of −n, wherein n=1, 2 or 3; each B comprises: ammonium ion and/or organic amine (B) cation, wherein 2. The foaming agent according to claim 1 , wherein (1a) H[OCH(R)CH(R)]— is H(OCHCH)— claim 1 , H(OCHCH(CH))— claim 1 , H(OCH(CH)CH)— claim 1 , H(OCHCH(CH))— claim 1 , H(OCH(CH)CH)— claim 1 , H(OCHCH(CHCl))— claim 1 , H(OCH(CHCl)CH)— or H(OCHCH(CBr))—.3. The foaming agent according to claim 1 , wherein: 'the pH of the foaming agent is 7.5-10.', 'the water content in the foaming agent is >0 wt % to 40 wt %; and/or'}4. The foaming agent according to claim 3 , wherein: the water content in the foaming agent is 5-35 wt %; and/or the pH of the foaming agent is 7.8-9.5.5. The foaming agent according to claim 4 , wherein: the water content in the foaming agent is 10-30 wt %; and/orthe pH of the foaming agent is 8-9.5.6. The foaming agent according to claim 1 , wherein:the total content of the compounds of the general formula (I) and water in the foaming agent is 70-100 wt %, based on the total weight of the foaming agent; and/or,the compound of the general formula (I) contains, on average, 1.5-5 of R groups per molecule.7. The foaming agent according to claim 6 , wherein: the total content of the compounds of the general formula (I) and water in the foaming agent is 80-99.0% claim 6 , based on the total weight of the foaming agent.8. The foaming agent according to claim 1 , wherein the organic amine (B) has m to m+3 of primary amine claim 1 , secondary amine and/or tertiary amine groups claim 1 , and optionally has quaternary ammonium group(s); and/or said organic amine compound (B) is an organic amine compound having 2-20 carbon atoms.9. The foaming agent according to claim 1 , wherein R claim 1 , R claim 1 , Ror Ris independently chosen from: H claim 1 , R claim 1 , C-Caliphatic hydrocarbyl group optionally ...

Steroids as Agonists for FXR

The invention relates to compounds of formula (I): 2. The method of claim 1 , wherein the composition is administered orally.3. The method of claim 1 , wherein the composition is administered intravenously.4. The method of claim 1 , wherein the amino acid conjugate of compound of formula (I) is a glycine conjugate of the compound of formula (I).5. The method of claim 1 , wherein the amino acid conjugate of compound of formula (I) is a taurine conjugate of the compound of formula (I).6. The compound of claim 1 , wherein the compound of formula (I) is radio labeled.7. The compound of claim 1 , wherein the compound of formula (I) is tritiated.8. The method of claim 1 , wherein the amino acid conjugate of compound of formula (I) is a conjugate of the compounds of formula (I) with any suitable amino acid.9. The method of claim 1 , wherein the amino acid conjugate of compound of formula (I) is a glycine and taurine conjugates of any of the compounds of formula (I) including pharmaceutically acceptable salts claim 1 , solvates or amino acid conjugates thereof. The present invention relates to Farnesoid X receptors (FXR). More particularly, the present invention relates to compounds useful as agonists for FXR, pharmaceutical formulations comprising such compounds, and therapeutic use of the same.Farnesoid X Receptor (FXR) is an orphan nuclear receptor initially identified from a rat liver cDNA library (B M. Forman, et al., 81:687-693 (1995)) that is most closely related to the insect ecdysone receptor. FXR is a member of the nuclear receptor family of ligand-activated transcription factors that includes receptors for the steroid, retinoid, and thyroid hormones (D J. Mangelsdorf, et al., 83:841-850 (1995)). Northern and in situ analysis show that FXR is most abundantly expressed in the liver, intestine, kidney, and adrenal (B M. Forman, et al., 81:687-693 (1995) and W. Seol, et al., 9:72-85 (1995)). FXR binds to DNA as a heterodimer with the 9-cis retinoic acid receptor (RXR ...

Synergistic compositions

The present invention describes a synergistic composition comprising of one or more statins, or one or more dipeptidyl peptidase IV (DPP IV) inhibitor or one or more biguanide antihyperglycaemic agent and a PPAR agonist of formula (Ia) for the treatment of diabetes, especially non-insulin dependent diabetes (NIDDM) or Type 2 diabetes and conditions associated with diabetes mellitus and to compositions suitable for use in such method. The invention also describes the preparation of such compositions. The present invention also relates to certain novel salts of the PPAR agonist of formula (I), processes for the preparation of these novel salts and use thereof.

STEROIDS AS AGONISTS FOR FXR

The invention relates to compounds of formula (I): 2. The method of claim 1 , wherein the composition is administered orally.3. The method of claim 1 , wherein the composition is administered intravenously.4. The method of claim 1 , wherein the amino acid conjugate of compound of formula (I) is a glycine conjugate of the compound of formula (I).5. The method of claim 1 , wherein the amino acid conjugate of compound of formula (I) is a taurine conjugate of the compound of formula (I).6. The compound of claim 1 , wherein the compound of formula (I) is radio labeled.7. The compound of claim 1 , wherein the compound of formula (I) is tritiated.8. The method of claim 1 , wherein the amino acid conjugate of compound of formula (I) is a conjugate of the compounds of formula (I) with any suitable amino acid.9. The method of claim 1 , wherein the amino acid conjugate of compound of formula (I) is a glycine and taurine conjugates of any of the compounds of formula (I) including pharmaceutically acceptable salts claim 1 , solvates or amino acid conjugates thereof. The present invention relates to Farnesoid X receptors (FXR). More particularly, the present invention relates to compounds useful as agonists for FXR, pharmaceutical formulations comprising such compounds, and therapeutic use of the same.Farnesoid X Receptor (FXR) is an orphan nuclear receptor initially identified from a rat liver cDNA library (B M. Forman, et al., 81:687-693 (1995)) that is most closely related to the insect ecdysone receptor. FXR is a member of the nuclear receptor family of ligand-activated transcription factors that includes receptors for the steroid, retinoid, and thyroid hormones (D J. Mangelsdorf, et al., 83:841-850 (1995)). Northern and in situ analysis show that FXR is most abundantly expressed in the liver, intestine, kidney, and adrenal (B M. Forman, et al., 81:687-693 (1995) and W. Seol, et al., 9:72-85 (1995)). FXR binds to DNA as a heterodimer with the 9-cis retinoic acid receptor (RXR ...

SYNERGISTIC COMPOSITIONS

The present invention describes a synergistic composition comprising of one or more statins, or one or more dipeptidyl peptidase IV (DPP IV) inhibitor or one or more biguanide antihyperglycaemic agent and a PPAR agonist of formula (1a) for the treatment of diabetes, especially non-insulin dependent diabetes or Type 2 diabetes and conditions associated with diabetes mellitus and to compositions suitable for use in such method. The invention also describes the preparation of such compositions. The present invention also relates to certain novel salts of the PPAR agonist of formula (I), processes for the preparation of: these novel salts and use thereof.

METHODS OF REDUCING COLOR IN ALKANOLAMINE COMPOSITIONS AND COMPOSITIONS PRODUCED THEREBY

A method of reducing color in an alkanolamine, the method comprising: contacting the alkanolamine with an amount of an aqueous solution effective to provide 5 to 1000 parts per million by weight of an alkali metal borohydride, based on parts by weight of the alkanolamine; and 0.5 to 10,000 parts per million by weight of an alkali metal hydroxide, based on parts by weight of the alkanolamine; preferably wherein the color-reduced alkanolamine is not distilled after the contacting. 1. A method of reducing color in an alkanolamine , the method comprising: 5 to 1000 parts per million by weight of an alkali metal borohydride, based on parts by weight of the alkanolamine; and', '0. 5 to 10,000 parts per million by weight of an alkali metal hydroxide, based on parts by weight of the alkanolamine., 'contacting the alkanolamine with an amount of an aqueous solution effective to provide'}2. The method of claim 1 , wherein the color-reduced alkanolamine is packaged for storage or transportation without distillation.3. The method of claim 1 , wherein the color-reduced alkanolamine has a Platinum-Cobalt Color Value claim 1 , Test Method ASTM D1209 claim 1 , of less than 50.4. The method of claim 1 , wherein the alkanolamine is{'sub': 1-10', '1-10', '1-10', '1-10', '2-4', '1-10', '2-4', '1-10', '2-4', '1-10', '1-10', '1-10', '1-10, 'a mono(Calkanol)amine, a di(Calkanol)amine, a tri(Calkanol)amine, an N—(Calkyl) mono(Calkanol)amine, an N—(Calkyl) di(Calkanol)amine, an N,N-di(Calkyl) (Calkanol)amine, an N—(Calkanol)pyrrolidine, an N—(Calkanol)imidazolidine, an N—(Calkanol)piperidine, an N—(Calkanol)piperazine, or a combination comprising at least one of the foregoing.'}5. The method of claim 1 , wherein the alkanolamine is a tri(Calkanol)amine.6. The method of claim 1 , wherein the aqueous solution comprises a total of 1 to 80 weight percent claim 1 , or 20 to 80 weight percent claim 1 , or 30 to 70 weight percent claim 1 , or 40 to 60 weight percent claim 1 , of the alkali metal ...

PROCESSES TO FORM ARILO PHOSPHITE COMPOSITIONS RENTED FROM COMPLEX HYDROCARBON CURRENTS

Procesos para alquilar compuestos de hidroxiarilo haciendo reaccionar un hidroxiarilo con al menos una olefina de una corriente de hidrocarburos compleja. La corriente de hidrocarburos compleja comprende con preferencia una fraccion de una corriente de alimentacion de hidrocarburos craqueada o productos de reaccion de una deshidrogenacion de una materia prima parafínica. La olefina de la corriente de hidrocarburos compleja es, con preferencia, una olefina ramificada, por ejemplo, isobutileno o isoamileno. Las composiciones alquiladas son apropiadas para formar composiciones líquidas de fosfito. Processes for renting hydroxyaryl compounds by reacting a hydroxyaryl with at least one olefin of a complex hydrocarbon stream. The complex hydrocarbon stream preferably comprises a fraction of a cracked hydrocarbon feed stream or reaction products of a dehydrogenation of a paraffinic raw material. The olefin of the complex hydrocarbon stream is preferably a branched olefin, for example, isobutylene or isoamylene. The alkylated compositions are suitable for forming liquid phosphite compositions.

Synthesis of deuterated morpholine derivatives

The present invention is directed to a process for preparing a 2,26,6- d 4 -morpholine derivative represented by Structural Formula (I), or a salt thereof.

Ionic liquids

Hydrolytically stable phosphite compositions

Hydrolytically stable phosphites as secondary antioxidants for polymer resins comprising a phosphite and an amine compound. The phosphite may be a liquid phosphite composition. The amine compound may have the structure of formula I: wherein x is 1, 2 or 3; R 1 is selected from the group consisting of hydrogen, and straight or branched C 1 -C 6 alkyl, and R 2 is selected from the group consisting of straight or branched C 1 -C 30 alkyl.

用于有机分子提纯、表面上具有正离子或质子化脂族残基的吸附剂

本发明涉及一种具有固体支承材料的吸附剂，所述吸附剂的表面具有如通式(I)的残基，其中所述残基通过共价单键连接到位于固体支承材料表面上的聚合物膜表面的官能团或者本体固体支承材料本身表面上的官能团。而且，本发明涉及所述吸附剂的用途，优选在色谱应用方面，其用于有机分子尤其是药学活性化合物的提纯。本发明涉及一种具有固体支承材料的吸附剂，所述固体支承材料的表面具有如通式(I)的残基，其中所述残基通过共价单键连接到位于固体支承材料表面上的聚合物膜表面上或者本体固体支承材料本身表面上的官能团。而且，本发明涉及所述吸附剂的用途，优选在色谱应用方面，其用于有机分子尤其是药学活性化合物的提纯。

一种含二氯乙酸双羟基季铵盐除草剂、其制备方法及应用

本发明公开了一种二氯乙酸双羟基季铵盐除草剂、其制备方法和应用。所述的二氯乙酸双羟基季铵盐除草剂结构通式表示：

Processes for forming alkylated aryl phosphite compositions from complex hydrocarbon streams

Hydrolysis-resistant phosphite compositions

FIELD: chemistry. SUBSTANCE: present invention relates to a composition, which is a liquid at ambient conditions, for stabilising polymers and method for stabilisation of the said composition ingredients, which may be used in chemical industry. The proposed composition comprises an amine of formula where x = 1 to 3, R 1 selected from H and C 1 -C 6 -alkyl, R 2 is a C 1 -C 30 -alkyl, and at least two phosphites of formula where R 3 , R 4 and R 5 are selected from C 4 -C 5 -alkylsubstituted C 6 -C 18 -aryls. The method for stabilisation includes addition of the said amine in the amount of 0.01 to 3 wt %. EFFECT: composition for stabilising polymers. 14 cl, 5 tbl, 5 ex РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2 563 457 C2 (51) МПК C07F 9/141 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ (21)(22) Заявка: ИЗОБРЕТЕНИЯ К ПАТЕНТУ 2012107446/04, 28.07.2010 (24) Дата начала отсчета срока действия патента: 28.07.2010 (72) Автор(ы): ХИЛЛ Джонатан (GB), ПАУЭР Морис (GB) (73) Патентообладатель(и): Эддивент Свицлэнд ГмбХ (CH) Приоритет(ы): (30) Конвенционный приоритет: R U 31.07.2009 US 61/230,654; 28.07.2010 US 12/804,793 (43) Дата публикации заявки: 10.09.2013 Бюл. № 25 2 5 6 3 4 5 7 (45) Опубликовано: 20.09.2015 Бюл. № 26 (85) Дата начала рассмотрения заявки PCT на национальной фазе: 29.02.2012 C 2 C 2 (56) Список документов, цитированных в отчете о поиске: Weston 399, Phosphite Antioxidant, 01.01.2007. US 5308648 A1, 03.05.1994. US 7629400 B2, 08.12.2009. RU 2119493 C1, 27.09.1998. RU 2126011 C1, 10.02.1999. EP 167969 A2, 15.01.1986. JP56113790 A, 07.09.1981. US3787537 A, 22.01.1974. WO 2007009916 A1, 25.01.2007. WO 2007149143 A2, 27.12.2007 (86) Заявка PCT: R U 2 5 6 3 4 5 7 US 2010/043469 (28.07.2010) (87) Публикация заявки PCT: WO 2011/014529 (03.02.2011) Адрес для переписки: 129090, Москва, ул. Большая Спасская, 25, стр. 3, ООО "Юридическая фирма "Городисский и Партнеры" (54) УСТОЙЧИВЫЕ К ГИДРОЛИЗУ ФОСФИТНЫЕ КОМПОЗИЦИИ (57) Реферат: Настоящее ...

Sorbent comprising on its surface a cationic or protonizable aliphatic residue for the purification of organic molecules

본 발명은 표면에 화학식 I의 잔기를 포함하는, 고체 지지 물질을 포함하는 흡착제에 관한 것으로, 여기서 상기 잔기는 단일 공유 결합을 통하여 벌크 고체 지지 물질 자체 또는 고체 지지 물질의 표면 위의 중합체 필름의 표면상 작용기에 결합된다. 추가로, 본 발명은 바람직하게는 크로마토그래피 적용에서 유기 분자, 특히 약제학적 활성 화합물의 정제를 위한 본 발명에 따르는 흡착제의 용도에 관한 것이다. The present invention relates to an adsorbent comprising a solid support material comprising a residue of formula (I) on its surface, wherein the residue is via a single covalent bond to the bulk solid support material itself or the surface of the polymer film on the surface of the solid support material. Bound to phase functional groups. In addition, the invention preferably relates to the use of the adsorbent according to the invention for the purification of organic molecules, in particular pharmaceutically active compounds, in chromatographic applications.

Ammonation of trialkanolamines

Lower trialkanolamines such as triethanolamine and triisopropanolamine are converted to the corresponding mono- and dialkanolamine by reacting with ammonia at about 150 DEG C.-275 DEG C. under superatmospheric pressure in the presence of a hydrogenation catalyst. The process is particularly useful for the recovery of alkanolamine values from still bottoms of alkanolamine production processes.

A kind of transparent nucleater and its preparation method and application

本发明提供了一种透明成核剂及其制备方法和用途，所述透明成核剂包含式(1)表示的化合物及其衍生物；所述方法包括：在溶剂中，使式(3)表示的化合物和式(4)表示的化合物接触，并浓缩结晶；以及透明成核剂在热塑性塑料中的应用。通过本发明的方法，可以获得透明成核剂，并且使用本发明的透明成核剂或者通过本发明的方法制得的透明成核剂可以有效地提高聚烯烃结晶速度，改变聚烯烃结晶体大小及结晶温度，以及提高聚合物制品的美感和良好的视觉感。特别是针对聚烯烃(例如聚丙烯、聚乙烯等)时，本发明的透明成核剂有着不可替代的优越性。

Method for producing higher ethanolamine

Method for synthesis of higher ethanolamines

FIELD: chemistry. SUBSTANCE: claimed invention deals with improved method of obtaining diethanolamine and/or triethanolamine. Method consists in reaction of glycolaldehyde with monoethanolamine and/or diethanolamine with molar ratio of monoethanolamine and/or diethanolamine to glycolaldehyde in the range from 1:1 to 50:1 in presence of solvent and catalyst, containing nickel, cobalt and/or copper. Activated catalyst, obtained by reduction of catalyst precursor, which can contain oxygen-containing compound of Ni, Co and/or Cu, is used for the process. Reaction is usually carried out at temperature from 15 to 350°C and pressure from 10 to 350 bar. In the process of method realisation glycolaldehyde is brought in contact with activated catalyst. Activated catalyst during and after its reduction up to bringing in contact with glycolaldehyde is used under inert conditions. Activated catalyst possesses reduction degree of 30% or higher. It is desirable for activated catalyst, obtained by reduction of passivated catalyst, after reduction to have reduction degree which is at least by 2% higher than degree of reduction of reduced passivated catalyst. Monoethanolamine and/or diethanolamine, which were obtained by reaction of glycolaldehyde with ammonia and/or monoethanolamine, can be used for reaction. EFFECT: method makes it possible to obtain products with high output and high selectivity. 10 cl, 2 tbl, 13 ex РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2 573 637 C2 (51) МПК C07C 209/28 (2006.01) C07C 215/10 (2006.01) C07C 215/12 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ (21)(22) Заявка: ИЗОБРЕТЕНИЯ К ПАТЕНТУ 2012129871/04, 13.12.2010 (24) Дата начала отсчета срока действия патента: 13.12.2010 Приоритет(ы): (30) Конвенционный приоритет: (43) Дата публикации заявки: 27.01.2014 Бюл. № 3 (56) Список документов, цитированных в отчете о поиске: DE 4400591 A1,13.07.1995. US 2003065224 A1,03. 04.2003. US 5023379 A,11.06.1991. EP 0238961 A2,30.09.1987. ...

Salt of aryl propionic acid compound and pharmaceutical application thereof

本发明提供了一种式Ⅰ化合物的碱加成盐、盐的晶型、制备方法，以及包含这些盐的药物组合物、制剂形式和制药用途。式Ⅰ化合物是一种属于芳基丙酸类的药学活性物质，以其为基础制备了新颖的盐型及其结晶形式，在水溶解性、溶出度、稳定性方面均好于式Ⅰ化合物。这些盐型及其结晶形式具有给药剂量小、药物起效快以及可以减小毒副作用和提高生物利用度等优点。含有式Ⅰ化合物的碱加成盐的药物组合物在制备镇痛、解热、消炎药物中具有广泛用途和广阔前景。

Process for producing hexahydrofurofuranol derivative, intermediate therefor, and process for producing the intermediate

本发明涉及医药合成领域，具体涉及六氢呋喃并呋喃醇衍生物的制备方法、其中间体及其制备方法。该制备方法包括卤化反应、酰化反应、酶法还原反应、与胺类化合物反应、还原关环反应步骤， 其中，R 1 ，R 2 ，R 3 为氢或羟基保护基；R 4 ，R 5 相同或不同地为苯基，烷基或取代苯基。在六氢呋喃并呋喃醇衍生物的制备过程中，通过酶法来构建手性，采用这样的技术手段能够非常高光学纯度制备得到产物。该制备方法能商业化生产制备达芦那韦关键中间体(3R,3aS,6aR)‑六氢呋喃并[2,3‑b]‑3‑醇，是一条非常经济，适合于工业化生产的路线。

Amino alcohol compounds and their use as zero or low VOC additives for paints and coatings

AMIN BASED COMPOSITION FOR CONTROL AND INHIBITION OF POLYMERIZATION OF STYRENE AND METHOD OF ITS USE

1. Композиция добавки на основе амина для контроля и ингибирования полимеризации ароматических виниловых мономеров, включающих стирол, содержащая:(a) одно или несколько из нитроксидных (т.е. нитроксильных) соединений; и(b) одно или несколько из ароматических нитросоединений, характеризующаяся тем, что указанная композиция дополнительно содержит один или несколько из(c) аминов,отличающаяся тем, что амин выбирают из группы, содержащей:(i) гидроксил алкильные третичные амины,(ii) третичные алкиламины,(iii) гидроксил алкильный первичный амин; и(iv) их смесь.2. Композиция добавки по п. 1, отличающаяся тем, что гидроксил алкильный третичный амин выбирают из группы, состоящей из трис(2-гидроксипропил) амина (TIPA); N,N,N',N'-тетракис(2-гидроксипропил) этилендиамина) (Quadrol); и N,N,N',N'-тетракис(2-гидроксиэтил) этилендиамина) (THEED).3. Композиция добавки по п. 1, отличающаяся тем, что указанный третичный алкиламин представляет собой трис [N-бутиламин] (ТВА).4. Композиция добавки по п. 1, отличающаяся тем, что указанный гидроксил алкильный первичный амин представляет собой моноэтаноламин (MEA).5. Композиция добавки на основе амина по п. 1, отличающаяся тем, что указанные нитроксидные (т.е. нитроксильные) соединения и указанные ароматические нитросоединения берут в соотношении, варьирующемся от примерно 99:1 до примерно 1:99 по массе.6. Композиция добавки по п. 1, отличающаяся тем, что указанная композиция содержит:a) примерно от 50 до примерно 99,5% по массе I) смеси указанных нитроксидных (т.е. нитроксильных) соединений и указанных ароматических нитросоединений; иb) примерно от 0,5 до примерно 50% по массе II) указанных аминов.7. Композиция добавки по п. 1, отличающаяся тем, ч РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (51) МПК C07C 7/20 (13) 2014 126 228 A (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ЗАЯВКА НА ИЗОБРЕТЕНИЕ (21)(22) Заявка: 2014126228, 16.11.2012 (71) Заявитель(и): ДОРФ КЕТАЛ КЕМИКАЛС (ИНДИЯ) ПРАЙВИТ ЛИМИТЭД (IN) Приоритет(ы ...

Absorbent for acidic gas separation

본 발명은 혼합가스로부터 산성가스를 분리하기 위하여 하기 화학식 1의 2-(이소프로필아미노)에탄올, 하기 화학식 2의 N-이소프로필디에탄올아민을 혼합하거나, 하기 화학식 3의 2-아미노-2-메틸-1-프로판올 또는 하기 화학식 4로 중 선택된 1종 이상의물질을 포함하는 것을 특징으로 하는 산성가스 분리용 흡수제에 관한 것이다. 본 발명에 따른 산성가스 분리용 흡수제는 기존의 모노에탄올아민 흡수제와 비교하여 산성가스의 흡수 속도 및 흡수량은 유사 또는 동등 이상이며, 흡수 후 산성가스의 탈거 속도 및 탈거량이 월등히 높아 동일 운전조건에서 산성가스 제거율 향상이 가능하고 탈거에 필요한 에너지를 줄일 수 있으므로 기존 흡수제 대비 경제성이 뛰어난 장점이 있다. 화학식 1 화학식 2 화학식 3 화학식 4 (상기 화학식 4에서 R 1 과 R 2 는 동일 또는 상이한 탄소수 2 또는 4의 알킬기, -(CH 2 ) 2 -OH, CH 2 -CH(OH)CH 3 또는 H, R 3 는 CH 3 또는 H)

Amine based additive composition for control and inhibition of polymerization of styrene, and method of use thereof

본 발명은 스티렌을 포함하는 방향족 비닐 단량체의 중합의 조절 및 억제를 위한 아민 기반 첨가제 조성물로서, (a) 하나 이상의 니트록사이드(즉, 니트록실) 화합물; 및 (b) 하나 이상의 방향족 니트로 화합물을 포함하고, 하나 이상의 (c) 아민을 더 포함하며, 상기 아민은 (i) 하이드록실 알킬 3차 아민, (ii) 3차 알킬 아민, (iii) 하이드록실 알킬 1차 아민; 및 (iv) 이들의 혼합물을 포함하는 군으로부터 선택되는 것을 특징으로 하는, 아민 기반 첨가제 조성물에 관련된다. 다른 구현 예에서, 본 발명은 또한 현재 제공된 조성물의 이용 방법에 관련된다. 또 다른 구현 예에서, 본 발명은 또한 현재 제공된 조성물을 이용하는 것에 의한 스티렌을 포함하는 방향족 비닐 단량체의 중합의 조절 및 억제 방법에 관련된다. 또 다른 구현 예에서, 본 발명은 또한 현재 제공된 조성물의 제조 방법에 관련된다. An amine-based additive composition for controlling and inhibiting polymerization of aromatic vinyl monomers comprising styrene comprising: (a) at least one nitroside (i.e., nitrosyl) compound; And (b) at least one aromatic nitro compound, wherein the amine further comprises at least one (c) amine, wherein the amine is selected from the group consisting of (i) hydroxylalkyl tertiary amine, (ii) tertiary alkylamine, (iii) hydroxyl Alkyl primary amines; And (iv) mixtures thereof. ≪ / RTI > In another embodiment, the invention also relates to methods of using the presently provided compositions. In another embodiment, the present invention also relates to a method of controlling and inhibiting polymerization of aromatic vinyl monomers comprising styrene by using the presently provided compositions. In another embodiment, the present invention also relates to a process for preparing the presently provided compositions.

4-((2-hydroxyethyl)(methyl)amino)-2-butanol and preparation method thereof

本发明公开了4‑((2‑羟乙基)(甲基)氨基)‑2‑丁醇及其制备方法，4‑((2‑羟乙基)(甲基)氨基)‑2‑丁醇的结构式为

NRF2 ACTIVATORS

РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2019 121 673 A (51) МПК C07D 498/04 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ЗАЯВКА НА ИЗОБРЕТЕНИЕ (21)(22) Заявка: 2019121673, 11.12.2017 (71) Заявитель(и): ГЛЭКСОСМИТКЛАЙН ИНТЕЛЛЕКЧУАЛ ПРОПЕРТИ ДИВЕЛОПМЕНТ ЛИМИТЕД (GB) Приоритет(ы): (30) Конвенционный приоритет: 15.12.2016 US 62/434,745 (85) Дата начала рассмотрения заявки PCT на национальной фазе: 15.07.2019 (72) Автор(ы): БРУКС, Карл А. (US), МЭТТЬЮЗ, Джей М. (US) R U (43) Дата публикации заявки: 15.01.2021 Бюл. № 2 (86) Заявка PCT: (87) Публикация заявки PCT: WO 2018/109646 (21.06.2018) A Адрес для переписки: 129090, Москва, ул. Б. Спасская, 25, стр. 3, ООО "Юридическая фирма Городисский и Партнеры" R U (57) Формула изобретения 1. Соединение, которое представляет собой (R)-3-(1,4-диметил-1Н-бензо[d][1,2,3] триазол-5-ил)-3-(3-(((R)-2-этил-2,3-дигидропиридо[2,3-f][1,4]оксазепин-4(5H)-ил)метил) -4-метилфенил)пропановую кислоту: или его фармацевтически приемлемая соли. 2. Соединение, которое представляет собой (R)-3-(1,4-диметил-1Н-бензо[d][1,2,3] триазол-5-ил)-3-(3-(((R)-2-этил-2,3-дигидропиридо[2,3-f][1,4]оксазепин-4(5H)-ил)метил) -4-метилфенил)пропановой кислоты (-)-1-дезокси-1-(метиламино)-D-глюцитоловую соль: Стр.: 1 A 2 0 1 9 1 2 1 6 7 3 (54) АКТИВАТОРЫ NRF2 2 0 1 9 1 2 1 6 7 3 IB 2017/057804 (11.12.2017) 2 0 1 9 1 2 1 6 7 3 R U A Стр.: 2 2 0 1 9 1 2 1 6 7 3 3. Фармацевтическая композиция, включающая соединение или его фармацевтически приемлемую соль по п. 1 и фармацевтически приемлемый эксципиент. 4. Фармацевтическая композиция, включающая соединение по п. 2 и фармацевтически приемлемый эксципиент. 5. Способ лечения респираторных и нереспираторных расстройств, включая ХОБЛ, астму, ALI, ARDS, фиброз, хроническую астму, острую астму, заболевание легких, обусловленное воздействием факторов окружающей среды, острую инфекцию легких, хроническую инфекцию легких, заболевание, связанное с α1 антитрипсином, кистозный фиброз, аутоимунные заболевания, ...

Use of ionic liquids

Salt of aryl propionic acid compound and pharmaceutical application thereof

本发明提供了一种式Ⅰ化合物的碱加成盐、盐的晶型、制备方法，以及包含这些盐的药物组合物、制剂形式和制药用途。式Ⅰ化合物是一种属于芳基丙酸类的药学活性物质，以其为基础制备了新颖的盐型及其结晶形式，在水溶解性、溶出度、稳定性方面均好于式Ⅰ化合物。这些盐型及其结晶形式具有给药剂量小、药物起效快以及可以减小毒副作用和提高生物利用度等优点。含有式Ⅰ化合物的碱加成盐的药物组合物在制备镇痛、解热、消炎药物中具有广泛用途和广阔前景。

Cyclohexyl-containing glycidyl ether

본 발명은 낮은 염소 함량 및 낮은 점도를 갖는 특징이 있으며 예컨대, 반응성 희석제, 가요제 또는 접착 강화제로서 에폭시 수지 배합물에서 사용될 수 있거나, 또는 그 자체로도 종합되어 거의 물을 흡수하지 않고 양호한 옥외 내후성을 갖는 피복제 또는 성형 수지로서 사용될 수 있는, 제 1항에 따른 일반식(Ⅰ) 내지 (Ⅳ)의 신규시클로헥실기 함유 글리시딜 에테르에 관한 것이다. The present invention is characterized by low chlorine content and low viscosity and can be used, for example, in epoxy resin formulations as reactive diluents, flexible agents or adhesion enhancers, or by themselves combined to have good outdoor weatherability with little water absorption. A novel cyclohexyl group-containing glycidyl ether of the general formulas (I) to (IV) according to claim 1, which can be used as a coating agent or a molding resin.

Lipids for delivery of active agents

Compounds are provided having the following structure: Formula (I) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R, R1, R2, G1, G2 and n are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.

Immunomodulatory compounds

提供的化合物可用作免疫调节剂。该化合物具有下式(II)：包括其立体异构体和药学上可接受的盐，其中R 1 、R 2a 、R 2b 、R 2c 、R 3 、R 4 、R 5 、R 6a 、R 6b 、m和n如本文所定义。还公开了与这些化合物的制备和使用相关的方法，以及包含这些化合物的药物组合物。

Polyether polyols providing good foam-gel balance for polyurethane products made therefrom

本发明公开一种叔胺引发剂和由其制备的聚合多元醇组合物，所述聚合多元醇组合物适用于制备聚氨基甲酸酯聚合物，尤其聚氨基甲酸酯泡沫。所述聚氨基甲酸酯聚合物泡沫展现机械特性、物理特性以及低散发的良好平衡。所述叔胺引发剂是二羟基叔胺与多羟基醇的反应产物，如N‑甲基乙醇胺与丙三醇的反应产物。

Polyether polyols providing good expansion-gelling balance for polyurethane products made from polyether polyols

Synergistic compositions

本發明描述用於治療糖尿病(特別是非胰島素依賴型糖尿病(NIDDM)或第2型糖尿病)和糖尿病相關性病況的協同性組成物，其包含一或多種他汀類(statins)、或一或多種二肽醯肽酶IV(DPP IV)抑制劑、或一或多種雙胍抗高血糖劑、與如式(Ia)之PPAR促效劑，及適合用於這類方法的組成物。本發明也描述這類組成物之製備。本發明也關於如式(I)之某些新穎的PPAR促效劑的鹽類，製備這些新穎鹽類之方法及其用途。 □

COMPOUNDS FOR USE IN CONTRAST PRODUCTS FOR RADIOGRAPHY.

L'invention a pour objet des composés non ioniques poly-iodés de formule générale: (CF DESSIN DANS BOPI) dans laquelle: R1 représente un groupe choisi parmi (CF DESSIN DANS BOPI) Ces composés sont utilisables dans des produits de contraste pour la radiographie. The subject of the invention is nonionic polyiodinated compounds of general formula: (CF DRAWING IN BOPI) in which: R1 represents a group chosen from (CF DRAWING IN BOPI) These compounds can be used in contrast products for radiography .

Process for the preparation of alkanolamine compounds

Process for the preparation of o-substituted hydroxylamines

PS/5-l7917/= Process for the preparation of O-substituted hydroxylamines Abstract O-substituted hydroxylamines of the formula I H2NOR1 (I) in which R1 is C1-C6alkyl, C1-C6haloalkyl,-CH2CR2=CR3R4 or -CH2C=CR5; R2 is hydrogen, halogen or methyl; R3 is hydrogen, halogen or methyl; R4 is hydrogen, halogen or methyl; and R5 is hydrogen, methyl or ethyl, are prepared by reacting a nitrile of the formula II R6-CN (II) in which R6 is C1-C4alkyl, phenyl or benzyl, is reacted with an alcohol of the formula III R7-OH (III) in which R7 is C1-C5alkyl, benzyl or C1-C4alkoxyethyl, in an organic solvent which is only sparingly miscible with water or not at all, in the presence of hydrogen halide HX, the suspension obtained of the iminoester hydrohalide of the formula IV (IV) in which R6 and R7 are as defined above and X is chlorine, bromine or iodine, is added at a controlled rate to an aqueous suspension of a carbonate or hydrogen carbonate at a temperature of from -3 to +5°C, an aqueous solution of a hydroxylamine salt is added to the mixture obtained at a temperature of from -20 to -5°C, the aqueous phase is separated off after the mixture has been warmed to room temperature, the solution obtained of the hydroximic acid ester of the formula V (V) in which R6 and R7 are as defined above, in an organic solvent is first treated with an aqueous solution of a strong base and then with an alkylating agent of the formula VI Y-R1 (VI) in which R1 is as defined above and Y is chlorine, bromine, iodine or -O-SO2R8, and R8 is C1-C4alkyl, C1-C4haloalkyl, phenyl or phenyl-substituted C1-C4alkyl, it being possible for the phenyl ring itself to be monosubstituted, disubstituted or trisubstituted by halogen or C1-C4alkyl, and Y is alternatively -OSO2OR1 if R1 is C1-C2alkyl, at from room temperature to the boiling point of the reaction mixture, the mixture is cooled to room temperature when the O-alkylation is complete, the aqueous phase is separated off, the oxime ether of the formula VII

COMPOUNDS FOR USE IN CONTRAST PRODUCTS FOR RADIOGRAPHY.

Process for producing substituted alkylamines

Mimics of acyl coenzyme-a, compositions thereof, and methods of cholesterol management and related uses

The invention relates to novel Acyl coenzyme-A mimics, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising a ketone compound. The Acyl coenzyme-A mimics, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, bacterial infection and impotence. In certain embodiments, the Acyl coenzyme-A mimics, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

Products obtained by conversion of glycolaldehyde derivatives and aminating agents and their conversion to ethylene amines and ethanolamines

一种制备亚乙基胺类和乙醇胺类的方法，其包括以下步骤：(i)在气相或液相中转化式(II)的乙醇醛衍生物，其中R 2 、R 3 相同或不同，为氢，烷基如C 1‑6 烷基，或环烷基如C 3‑6 环烷基；和式(III)的胺化剂，其中R 1 为氢(H)、烷基如C 1‑6 烷基，或环烷基如C 3‑6 环烷基；(ii)将步骤(i)中获得的反应产物供入到氢化反应器中，其中在氢化催化剂存在下用氢气转化所述反应产物。

Compounds used in x-ray contrast agents

Non-ionic poly-iodized compounds of general formula (I) in which R1 is a group selected from (a), R2 is a group selected from -COR1 and (b). Said compounds are used in contrast products for radiography.

Zirconium-based cross-linker compositions and their use in high ph oil field applications

A cross-linking composition which comprises (a) an aqueous liquid, (b) a cross-linkable organic polymer, and (c) a solution comprising a zirconium cross-linking agent which comprises a zirconium complex having a molar ratio of 1:2 to 1:4 of zirconium to triethanolamine and a molar ratio of 1:0.1 to 1:1 of zirconium to N,N,N,N -tetrakis-(2-hydroxypropyl)-ethylene diamine. The composition can be used in oil field applications for hydraulic fracturing and plugging of permeable zones and leaks in subterranean formations.

Compounds used in contrast products for radiography

Non-ionic poly-iodized compounds of general formula (I) in which R1 is a group selected from (a), R2 is a group selected from -COR1 and (b). Said compounds are used in contrast products for radiography.

Synthesis of deuterated morpholine derivatives

The present invention is directed to a process for preparing a 2,26,6-d 4 -morpholine derivative represented by Structural Formula (I): or a salt thereof.

Liquids

Method for preparing hexahydrofuro-furanol derivative, intermediate thereof and preparation method therefor

The invention relates to the field of pharmaceutical synthesis, in particular to the preparation method of hexahydrofuro-furanol derivative, intermediates thereof and preparation methods thereof. The preparation methods comprises the steps of halogenation reaction, acylation reaction, enzymatic reduction reaction, reaction with amine compounds, reduction ring closure reaction (A1, A2, B, Cp1, C_L, Cf)wherein, R₁, R₂, R₃ are hydrogen or hydroxy protecting groups; R₄ and R₅ are the same or different and are phenyl, alkyl or substituted phenyl. In the preparation process of hexahydrofuro-furanol derivatives, the chirality is constructed by enzymatic method, and the product can be prepared with very high optical purity by adopting such technical means. The preparation method can be used to prepare the key intermediate, (3R, 3aS, 6aR)-hexahydrofuro[2,3-b]-3-ol, of Darunavir, in commercial production, which is a very economical route suitable for industrial production.

Process for preparing bis-(hydroxyalkyl) secondary alkyl amines

A process for preparing bis-(hydroxyalkyl) secondary alkyl amines which comprises reacting, at elevated temperatures and pressures, secondary alkyl primary amines with alkylene oxides in the presence of a phenol catalyst.

Aminoalcohol compounds and their use as zero or low VOC additives for paints and coatings

Provided are aminoalcohol compounds for use as additives for paints and coatings. The compounds are of the formula (I): wherein x, R, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and R A are as defined herein.

Novel glycidyl ether containing cyclohexyl group

Liquids

The present invention relates to ionic liquid comprising an anion and a cation wherein the cation is a primary, secondary or tertiary ammonium ion containing a protonated nitrogen atom.

Compound with organic amine salt, having anion as co2 donor and use thereof as foaming agent

FIELD: chemistry. SUBSTANCE: invention relates to a foaming agent containing a compound of an organic amine salt of formula (I) or a mixture of compounds of organic amine salts of formula (I). Formula (I): A n- [B m+ ] p (I), where A n- is an anion - source of CO 2 , having -n valence, where n = 1, 2 or 3, B m+ is or contains an ammonium ion with valence +1 and/or one or more organic amine (B) cations, in which each cation (B) has - + NR 3 R 4 H group and/or a group - + NR 3 H- in an amount of m, where m = 1–5, 0 < p ≤ (n/m), and where organic amine (B) is an organic amino compound (B) having from 2 to 50 carbon atoms. Value A n- is as specified in the claim. Compound of an organic amine salt of general formula (I) or a mixture of compounds of an organic amine salt of formula (I) contains 22–96 wt. % monoamino alcohol salts and diamine alcohol salts based on the total weight of the compound of the organic amine salt of formula (I) or a mixture of compounds. Content of water in the foaming agent ranges from more than 0 to 40 wt. %. Also disclosed are methods of producing a foaming agent, a foaming composition for producing foamed polyurethane and foamed polyurethane material. EFFECT: disclosed foaming agent can be uniformly dispersed in a foaming composition for uniform foaming, and cells in foamed polyurethane have uniform distribution and uniform size of cells. 21 cl, 16 dwg, 6 tbl, 66 ex РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (51) МПК C07C 269/00 (2006.01) C07C 271/02 (2006.01) C07C 213/04 (2006.01) C07C 213/08 (2006.01) C07C 215/08 (2006.01) C07C 215/12 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА C07C 51/41 (2006.01) ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ C07C 68/06 (2006.01) C07C 69/96 (2006.01) C08J 9/08 (2006.01) (12) (13) 2 716 711 C1 C08G 18/48 (2006.01) C08G 18/42 (2006.01) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ (52) СПК C07C 269/00 (2020.01); C07C 271/02 (2020.01); C07C 211/14 (2020.01); C08G 18/165 (2020.01); C08G 18/2036 (2020.01); C08G 18/242 (2020.01); C08G 18/246 (2020.01); C08G ...

Steroids as agonists for fxr

The invention relates to compounds of formula (I) wherein R is ethyl, propyl or allyl, and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof. The compounds of formula (I) are useful as FXR agonists.

2-aminoalkyl-1,4-diaminobenzene derivatives and colorants containing these compounds

Long chain amine salts

Zirconium-based cross-linker compositions and their use in high PH oil field application

Zirconium-based cross-linker compositions and their use in high ph oil field applications

A cross-linking composition which comprises (a) an aqueous liquid, (b) a cross-linkable organic polymer, and (c) a solution comprising a zirconium cross-linking agent which comprises a zirconium complex having a molar ratio of 1:2 to 1:4 of zirconium to triethanolamine and a molar ratio of 1:0.1 to 1:1 of zirconium to N,N,N,N -tetrakis-(2-hydroxypropyl)-ethylene diamine. The composition can be used in oil field applications for hydraulic fracturing and plugging of permeable zones and leaks in subterranean formations.

Polyiodes compounds: preparation process; diagnostic composition.

Mimics of acyl coenzyme-a, compositions thereof, and methods of cholesterol management and related uses

Syntheses of substituted amines

Hydrocarbyl sulfates are reacted with alkoxy amines. The resulting substituted amines can be ethoxylated, quaternized and/or oxidized to form detersive surfactants.

Combretastatin a-4 phosphate prodrug salts with nitrogen-containing compounds

Provided herein are novel and useful combretastatin A-4 prodrug salts that increase the solubility of combretastatin A-4, readily regenerate combretastatin A-4 in vivo under normal physiological conditions, and which produce physiologically tolerable products as a result of the regeneration of combretastatin A-4.

Combretastatin a-4 phosphate prodrug mono- and di-organic amine salts, mono- and di-amino acid salts, and mono- and di-amino acid ester salts

본 발명은 콤브레타스타틴 A-4의 용해도를 증가시키고, 정상적인 생리 조건 하에서 생체내 콤브레타스타틴 A-4를 쉽게 재생시킬 수 있으며, 콤브레타스타틴 A-4 재생 결과로서 생리적으로 내성인 생성물을 생성하는 신규하고 유용한 콤브레타스타틴 A-4 프로드럭 염을 제공한다. The present invention increases the solubility of combretastatin A-4, can easily regenerate in vivo combretastatin A-4 under normal physiological conditions, and is physiologically resistant as a result of combretastatin A-4 regeneration. Provided are new and useful combretastatin A-4 prodrug salts that yield products.

NON-IONIC POLY-IODIC COMPOUNDS AND PROCEDURE FOR THE PREPARATION.

La presente invención se refiere a compuestos utilizables en productos de contraste para la radiografía. Se utilizo después de mucho tiempo como productos de contaste los compuestos iodobensénicos que presentan sobre el núcleo benzénico numerosos átomos de iodo, en general 3 átomos de iodo por núcleo de benzénico, y diversos otros sustitutos.

Agrochemical compositions and surfactant compounds

Agrochemical compositions including compounds of the general formula (I): R1-(R2)X1-[Link]-R3 where R1 is polyhydroxy hydrocarbyl; R2 is H or hydrocarbyl, or is a group as defined for R1; X1 is a nitrogen containing group as defined, Link is a linking group of the formula (II): -CH2-CHOH-X2- where X2 is as defined and R3 is hydrocarbyl, usually C6 to C30, hydrocarbyl. The compounds of the formula (I) can function as emulsifiers, dispersants or, and particularly, as adjuvants. The agrochemical can be a plant growth reguators, herbicides, and/or pesticides, for example insecticides, fungicides, acaricides, nematocides, miticides, rodenticides, bactericides, molluscicides and/or a bird repellent. Particularly useful formulations include water soluble herbicide(s), particularly such as Glyphosate, Sulfosate, Glufosinate and Paraquat. The invention further includes compounds of the formula (IIa): R1-(R2)X1-[Link1]-R3 where R1, R2, and R3 are as defined above for formula (I); and Link1 is a defined linking group; and compounds of the formula (IIb): R1-(R2)X1a-[Link2]-R3 where R1, R2, and R3 are as defined above for formula (I); X1a is a nitrogen containing group as defined and Link2 is a defined linking group.

DI- (TERT.-BUTANOL) AMINE AND METHOD FOR THE PRODUCTION THEREOF BY HYDRATING 2 (1-HYDROXY-1-METHYL-ETHYL) -5,5-DIMETHYL-1,3-OXAZOLINE

Polyiodinated compounds, process for their preparation and diagnostic composition

Synthesis and application of alcohol amine with lengthened main carbon chain

一种主碳链加长的醇胺合成及应用，属于化学建材领域。在催化剂作用下,三元醇胺经过两步取代反应、水解反应和还原反应得到新型醇胺(NAA)。本发明得到的新型醇胺作为水泥助磨剂添加到水泥中,比三乙醇胺拥有更好的助磨效果,具有广泛的应用前景。

Method for producing higher ethanolamines

本发明涉及一种通过使羟基乙醛与单乙醇胺和/或二乙醇胺在催化剂存在下反应而制备乙醇胺类的方法。

Ionic liquids comprising nitrogen containing cations

本发明涉及包含阴离子和阳离子的离子液体，其中所述阳离子为包含质子化的氮原子的伯、仲或叔铵离子。

Polyiodes compounds: process of preparation; diagnostic composition.

L'invention a pour objet des composés benzéniques hexasubstitués tétraiodés ou pentaiodés comprenant au moins 10 groupes OH utiles comme agents de contraste dans le domaine du diagnostic. L'invention a également pour objet les compositions de formule générale I: (CF DESSIN DANS BOPI) dans laquelle R1 , R2 , R3 , R4 , R5 et R6 sont choisis parmi un atome d'iode et les groupes suivants: (CF DESSIN DANS BOPI) sous réserve qu'au moins 4 groupes et au maximum 5 groupes parmi parmi R1 , R2 , R3 , R4 , R5 et R6 , représentent un atome d'iode et sous réserve qu'au moins 8 groupes OH soient présents par molécule de formule I. The subject of the invention is tetraiodinated or pentaiodinated hexasubstituted benzene compounds comprising at least 10 OH groups which are useful as contrast agents in the field of diagnosis. A subject of the invention is also the compositions of general formula I: (CF DRAWING IN BOPI) in which R1, R2, R3, R4, R5 and R6 are chosen from an iodine atom and the following groups: (CF DRAWING IN BOPI) BOPI) with the proviso that at least 4 groups and at most 5 groups among R1, R2, R3, R4, R5 and R6, represent an iodine atom and provided that at least 8 OH groups are present per molecule of formula I.

Composition comprising a pesticide and an alkoxylate of 2-propylheptylamine

The invention relates to a compound comprising a pesticide and an alkoxylate. The invention further relates to the alkoxylate, to a method for the production thereof, and to the use thereof as an auxiliary agent in pesticide-containing spray mixtures. The invention further relates to a method for controlling phytopathogenic fungi and/or undesirable plant growth and/or undesirable insect or mite infestation and/or for regulating the growth of plants, wherein the compound is allowed to act on the respective pests, the habitat thereof or the plants to be protected from the respective pest, the ground and/or undesirable plants and/or the useful plants and/or the habitat thereof. The invention further relates to seed containing the compound. (see formula A) (see formula AQ)

Compound with an organic amine salt, having an anion as a co2 donor, and its use as a foaming agent

FIELD: chemistry. SUBSTANCE: invention relates to foaming agent containing a compound of an organic amine salt of formula (I) or a mixture of compounds of organic amine salts of formula (I). Formula (I): A n- [B m+ ] p (I), where A n- – anion – source of CO 2 , having -n valency, where n=1, 2 or 3, B m+ is or contains an ammonium ion with a valence of +1 and/or one or more organic amine cations (B), in which each cation (B) has a group - + NR 3 R 4 H and/or group - + NR 3 H- in amount of m, where m=1–5, 0<p≤(n/m), and where the organic amine (B) is an organic amine compound (B) having from 2 to 50 carbon atoms. Values of A n- such as specified in the claim. Compound of an organic amine salt of general formula (I) or a mixture of compounds of an organic amine salt of formula (I) contains 25–95 wt% monoamino alcohol salts and a salt of diamine alcohols based on the total weight of the compound of the organic amine salt of formula (I) or a mixture of compounds. Content of water in the foaming agent is >0 wt% to 40 wt%. Also disclosed are methods of producing a foaming agent, a foaming composition for producing foamed polyurethane and foamed polyurethane material. EFFECT: proposed foaming agent can be uniformly dispersed in a foaming composition for uniform foaming, and cells in foamed polyurethane have uniform distribution and uniform size of cells. 21 cl, 16 dwg, 6 tbl, 66 ex РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (51) МПК C07C 269/00 (2006.01) C07C 271/12 (2006.01) C07C 213/04 (2006.01) C07C 215/08 (2006.01) C07C 215/12 (2006.01) C07C 51/41 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА C07C 68/06 (2006.01) ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ C07C 69/96 (2006.01) C08J 9/08 (2006.01) C08G 18/48 (2006.01) (12) (13) 2 708 457 C1 C08G 18/42 (2006.01) C08K 5/521 (2006.01) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ (52) СПК (21)(22) Заявка: 2018146942, 11.05.2017 11.05.2017 (73) Патентообладатель(и): ШАНЬДУН ЮНИВЕРСИТИ ОФ ТЕКНОЛОДЖИ (CN) Дата регистрации: 09.12.2019 Приоритет(ы): (30) Конвенционный ...

For controlling and suppress compositions of additives based on amine and the using method thereof of cinnamic polymerization

本发明涉及基于胺的添加剂组合物，其用于控制及抑制包括苯乙烯的芳族乙烯基单体聚合，该组合物包含（a）一种或多种氮氧化物（即硝酰基）化合物；及（b）一种或多种芳族硝基化合物，其特征在于该组合物进一步包含一种或多种（c）胺，其中该胺选自：（i）羟基烷基三级胺；（ii）第三烷基胺；（iii）羟基烷基一级胺；及（iv）其混合物。在一个实施例中，本发明也涉及使用本发明提供的组合物的方法。在另一个实施例中，本发明也涉及通过采用本发明提供的组合物来控制及抑制包括苯乙烯的芳族乙烯基单体聚合的方法。在另一个实施例中，本发明也涉及本发明提供的组合物的制备方法。

Organic amine salt compound having anions serving as co2 donors and application of same as foaming agent

An organic amine salt compounds of general formula A n- [B m+ ] p (I) is disclosed, wherein A n- is a CO 2 -donating anion with a valence of -n, wherein n = 1, 2 or 3; each B m+ comprises: ammonium ion, hydrazinium ion and/or organic amine B cation; wherein m = 1-10; 0 < p ≤ n m ; and wherein A n- is one or more selected from a group consisting of following anions: (a) carbamate orcarbazate; (b) carbonate; (c) formate; (d) bicarbonate; (e) organic monocarbonate; (f) organic poly-carbamate; (g) orthoformate; or (h) organic poly-carbonate. The compound of general formula (I) has at least one of hydroxyalkyl group linked to N atom, i.e., has alkanolamine residue. They can be used as polyurethane foaming agent, and most of them can be used as polystyrene foaming agent or polyvinyl choride foaming agent.

New aluminum compound for bonding glass and/or ceramics, sealing cracks in glasses and/or ceramics, eliminating craquelure, and fixing and/or restoring archaeological findings of glass and/or ceramic

Aluminum compound (I), is new. Aluminum compound of formula (Al(OH) 3 - x[(O(CH 2) n)-N-((CH 2) nOH) 2] x) (I), is new. n : 1-18; and x : 1 or 2. Independent claims are also included for: (1) an adhesive comprising (I); and (2) the preparation of (I).

COMPOSITION INCLUDING PESTICID AND ALCOXYLATE 2-PROPYLHEPYLAMINE

Объектом настоящего изобретения является композиция, включающая пестицид и алкоксилат. Кроме того, изобретение относится к алкоксилату, к способу его получения и к его применению в качестве вспомогательного вещества в жидкостях для опрыскивания, содержащих пестицид. Далее, изобретение относится к способу борьбы с фитопатогенными грибами, и/или нежелательным ростом растений, и/или нежелательным поражением насекомыми или клещами, и/или регуляции роста растений, причем композицией воздействуют на соответствующих вредителей, их жизненное пространство или на подлежащие защите от соответсвующего вредителя растения, почву, и/или на нежелетельные растения, и/или технические культуры и их жизненное пространство. Далее, изобретение относится к посевному материалу, содержащему композицию. The object of the present invention is a composition comprising a pesticide and alkoxylate. In addition, the invention relates to alkoxylate, to a method for its preparation and to its use as an auxiliary substance in spray liquids containing a pesticide. The invention further relates to a method for controlling phytopathogenic fungi, and / or undesired plant growth, and / or undesired insect or mite damage, and / or plant growth regulation, the composition affecting the respective pests, their living space, or those to be protected from the corresponding pest plants, soil, and / or undesirable plants, and / or industrial crops and their living space. The invention further relates to seed containing the composition.

Steroids as agonists for FXR

The invention relates to compounds of formula (I): wherein R is ethyl, and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof. The compounds of formula (I) are useful as FXR agonists.

Mimics of acyl coenzyme-a, compositions thereof, and methods of cholesterol management and related uses

The invention relates to novel Acyl coenzyme-A mimics, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising a ketone compound. The Acyl coenzyme-A mimics, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, bacterial infection and impotence. In certain embodiments, the Acyl coenzyme-A mimics, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

Process for preparing 1,2-dimethyl-4- (d-ribitylamino) -benzene.

Synthesis of substituted amines

Composition comprising a pesticide and a 2-propylheptylamine alkoxylate

El objeto de la invención es una composición que comprende un pesticida y un alcoxilato. Además, la invención se refiere al alcoxilato, un proceso para su preparación, y su uso como agente auxiliar en caldos de pulverización que contienen pesticida. La invención se refiere, además, a un proceso para combatir hongos fitopatógenos y/o el crecimiento de plantas indeseadas y/o la infestación indeseada por insectos y ácaros y/o para regular el crecimiento de plantas, haciendo actuar la composición sobre las respectivas plagas, su hábitat o las plantas a proteger de la correspondiente plaga, el suelo y/o sobre plantas indeseadas y/o las plantas útiles y/o su hábitat. Además, la invención se refiere a simiente que contiene la composición. The object of the invention is a composition comprising a pesticide and an alkoxylate. In addition, the invention relates to alkoxylate, a process for its preparation, and its use as an auxiliary agent in spray broths containing pesticide. The invention also relates to a process to combat phytopathogenic fungi and / or the growth of unwanted plants and / or unwanted infestation by insects and mites and / or to regulate plant growth, by acting on the composition of the respective pests. , its habitat or the plants to be protected from the corresponding pest, the soil and / or on unwanted plants and / or useful plants and / or their habitat. In addition, the invention relates to seed containing the composition.

A kind of long-life room temperature phosphorimetry material and its preparation method and application

本发明公开了一种长寿命室温磷光材料及其制备方法和应用，通过在有机芳环结构中引入酚羟基，制备酚阴离子和胺阳离子形成的配合物，所制得的磷配合物溶液可在空气中直接用溶液旋涂或滴涂成膜从而得到处于高度无定型态而稳定性极佳的室温磷光材料，该方法操作简便高效。该薄膜态室温磷光材料，实现了可接触空气而无需额外保护的长寿命室温磷光性能，磷光寿命长达0.14s。另外，由于兼具优良的气体通透性与空气中的磷光高稳定性，该长寿命室温磷光材料在传感、催化等领域具有很好的应用价值。

Process for making ethanolamines

물-암모니아 용액을 산화에틸렌과 반응시킴으로써 미반응된 암모니아, 물, 및 에탄올아민류를 함유하는 배출 반응 혼합물을 형성하는 것을 포함하는, 에탄올아민류의 제조 방법. 상기 배출 반응 혼합물은 이후 그 중에서도 특히 상기 에탄올아민류를 분리하기 위한 일련의 단계들을 거치게 된다.